ISSN: 3029-0872

Case Report

Journal of Medical and Clinical Nursing Studies

Panic Disorder: Epidemiology, Etiology, and Treatment Strategies

Dr. Eda Gorbis[1*] and Aanya Jajoo[2]

[1]*The Westwood Institute for Anxiety Disorders, Los Angeles, CA, United States*
[2]*University of California, Los Angeles, CA, United States*

[*]**Corresponding author**
Eda Gorbis, The Westwood Institute for Anxiety Disorders, 921 Westwood Blvd., Suite 223, Los Angeles, California 90024, United States.

Received: July 29, 2024; **Accepted:** September 03, 2024; **Published:** September 07, 2024

ABSTRACT
Panic disorder is a complex and debilitating anxiety disorder characterized by recurrent, unexpected panic attacks and associated anticipatory anxiety. This comprehensive review synthesizes current knowledge on the epidemiology, etiology, biology, and treatment of panic disorder. We discuss the prevalence, comorbidities, genetic factors, and neurobiological mechanisms underlying panic disorder, including detailed explorations of the noradrenergic and serotonergic systems. Additionally, we examine various treatment approaches, including pharmacological interventions (antidepressants and benzodiazepines) and cognitive-behavioral therapies, highlighting their efficacy, limitations, and long-term outcomes. This in-depth overview provides insights into the multifaceted nature of panic disorder, emphasizing the importance of a comprehensive approach to its management and suggesting directions for future research.

Introduction

Panic disorder is a significant mental health condition affecting approximately 2% of the general population. It is characterized by sudden, intense episodes of fear or discomfort, known as panic attacks, which are often accompanied by physical symptoms such as heart palpitations, shortness of breath, and dizziness. These attacks can lead to anticipatory anxiety and avoidance behaviors, potentially resulting in agoraphobia. The term "panic" originates from Pan, the ancient Greek god of woods and fields, who was believed to be responsible for the sudden, inexplicable fear experienced in lonely places. Modern understanding of panic disorder, however, recognizes it as a distinct clinical entity with its own etiology and treatment approaches.

This review aims to provide a comprehensive overview of panic disorder, focusing on its epidemiology, etiology, biological underpinnings, and current treatment strategies. We hope to contribute to a better understanding of this complex disorder and inform future research and clinical practice.

Epidemiology

Prevalence and Demographics

Panic disorder affects approximately 2% of the general population, with only about one-third of cases receiving treatment. The onset typically occurs in young adulthood, between the ages of 20 and 30, although it can also manifest in children. There is a decline in new cases after age 55. Women are twice as likely as men to develop panic disorder with agoraphobia.

Panic disorder is associated with a history of separation anxiety and shyness in childhood. Kagan et al. at Harvard Infant Study Lab identified certain infants with colic, sleeplessness, and irritability who later exhibited behavioral inhibition and marked physiological arousal in novel situations during toddlerhood. This pattern, termed "behavioral inhibition to the unfamiliar," is associated with a high rate of anxiety disorders by ages 6-9 [1-9].

Comorbidities

Panic disorder frequently co-occurs with other psychiatric conditions. Major depression affects 56% of patients with panic disorder, while about 20% of patients with major depression have panic attacks (Noyes and Perry). Personality disorders are present in 30-60% of panic disorder patients, although many of these personality-related symptoms improve with successful treatment of panic disorder.

Other common comorbidities include social phobia (30%), simple phobia (30%), and generalized anxiety disorder (GAD)

Citation: Eda Gorbis, Aanya Jajoo. Panic Disorder: Epidemiology, Etiology, and Treatment Strategies. J Med Clin Nurs Stud. 2024. 2(5): 1-5.
DOI: doi.org/10.61440/JMCNS.2024.v2.59

(21%). The Epidemiological Catchment Area (ECA) study found that individuals with panic disorder have twice the risk of developing alcoholism compared to the general population. Additionally, derealization and depersonalization may occur in approximately one-third of panic disorder patients. The ECA study also found that panic disorder is equal to or greater than depression in terms of physical and emotional consequences, alcohol and drug abuse, impaired social functioning, and financial dependency.

Course and Prognosis

Panic disorder often follows a chronic course with acute exacerbations and periods of remission. The Massachusetts General Hospital (MGH) study revealed that while some patients experience true remission, many continue to have residual symptoms and are prone to relapse. Patients with phobic avoidance were less likely to experience remission (19% remission rate). Patients with a childhood anxiety diathesis showed a more chronic course and higher comorbidity. Panic symptoms tend to wax and wane, often unrelated to stress. Phobic avoidance can develop early or late in the course of the disorder. Patients often become focused on situations away from perceived safety and may become overly dependent. Suicidal thoughts and gestures in panic disorder patients occur at rates similar to those seen in major depression, with some studies suggesting even higher rates of completed suicides.

Etiology and Risk Factors

Genetic Factors

Evidence suggests a strong genetic component in panic disorder. There is a high concordance rate observed in identical twins compared to dizygotic twins. Furthermore, it is evident that there are elevated rates of anxiety disorders in children of individuals with panic disorder, particularly separation anxiety. Increased panic disorder in first-degree relatives of panic disorder probands, but not in relatives of those with GAD is observed. The genetic link appears to be specific to panic disorder and does not extend to GAD.

Psychological Factors

Several psychological theories and factors have been proposed to contribute to the development of panic disorder. Attachment theory, as proposed by John Bowlby, suggests that anxiety is caused by the loss of attachment between child and mother. Klein suggested that panic attacks may represent an overreaction of the instinctual response to loss of attachment. High levels of separation anxiety in childhood are associated with the later development of panic disorder. One study found a correlation between panic attacks and overprotective fathers. Three studies have shown that people with panic attacks have experienced more traumatic life events than control groups without panic attacks. These events are usually separation related. There is evidence that certain individuals interpret physiological sensations in a catastrophic way, contributing to the development of panic attacks. Often, minor illnesses can precipitate panic attacks such as influenza.

Environmental Factors

Common precipitants of panic attacks in adults include disruption in attachment bonds, changes in psychosocial stability and physiological changes. Cross-cultural studies have highlighted the importance of cultural context in the manifestation and interpretation of panic symptoms. For instance, “Kayak Angst” is a form of panic disorder observed among the Inuit people of Greenland. This condition involves intense fear and panic attacks occurring while hunting alone in kayaks, reflecting the unique environmental and cultural stressors faced by the Inuit. Such studies underscore the role of cultural factors in shaping the experience of panic disorders, suggesting that symptoms can vary significantly across different cultural settings

Biology of Panic Disorder

Neuroanatomy

The locus coeruleus (LC), the principal norepinephrine-containing nucleus in the brain, has been implicated in the pathophysiology of panic disorder. The LC provides noradrenergic innervation to various brain regions involved in fear and anxiety responses, including the cerebral and cerebellar cortices, hippocampus, limbic system, brain stem, and spinal cord. This widespread innervation allows the LC to influence various physiological correlates of fear, such as increased heart rate and dry mouth.

Neurotransmitter Systems

Noradrenergic System

The noradrenergic system, particularly the locus coeruleus, plays a crucial role in panic disorder. Increased norepinephrine levels and higher MHPG (a norepinephrine metabolite) is present in the cerebrospinal fluid of anxious patients. Yohimbine, a norepinephrine agonist, can induce panic attacks in individuals with panic disorder. Uncontrollable stress increases LC-NE firing. Effective anti-panic medications can often decrease noradrenergic activity by lowering tyrosine hydroxylase activity, decreasing the firing rate of the LC, reducing NE turnover and decreasing sensitivity of postsynaptic β-adrenergic receptors. However, the noradrenergic system alone cannot fully explain panic disorder, as some effective treatments (like fluvoxamine) primarily affect other neurotransmitter systems.

Serotonergic System

The serotonergic system also plays a crucial role in panic disorder. Selective serotonin reuptake inhibitors (SSRIs) have proven to be effective in treating panic disorder. Serotonin precursors can alleviate panic symptoms. MCPP, a serotonin agonist, increases anxiety and panic in susceptible individuals. Clomipramine, which has strong serotonergic effects, works more quickly than imipramine in blocking panic and reversing phobic avoidance. The interaction between the noradrenergic and serotonergic systems is likely important in the pathophysiology of panic disorder, with the serotonergic system possibly modulating the noradrenergic system.

Neuroimaging Findings

PET scan studies have revealed abnormalities in brain activity during panic attacks and in between attacks in individuals with panic disorder. These findings provide further evidence for the biological basis of the disorder and may help guide future treatment approaches.

Other Biological Factors

Several other biological factors have been implicated in panic disorder. Evidence suggests congenital baseline autonomic hyperarousal in panic patients. For example, children of agoraphobic mothers have higher heart rates when introduced

to new situations compared to children of non-agoraphobic mothers. Challenges involving lactate, isoproterenol, epinephrine, bicarbonate, hyperventilation, CO2, and hypoxia can induce panic symptoms, suggesting a link between panic and respiratory function. Activation of β-receptors can stimulate anaerobic glycolysis and lactate production, potentially contributing to panic symptoms.

Clinical Presentation and Diagnosis

Symptoms of Panic Attacks

Panic attacks are characterized by intense fear or discomfort, reaching a peak within minutes, and include at least four of the following symptoms:

1. Palpitations or accelerated heart rate
2. Sweating
3. Trembling or shaking
4. Shortness of breath or feeling of smothering
5. Feelings of choking
6. Chest pain or discomfort
7. Nausea or abdominal distress
8. Feeling dizzy, unsteady, lightheaded, or faint
9. Derealization or depersonalization
10. Fear of losing control or going crazy
11. Fear of dying
12. Paresthesias (numbness or tingling sensations)
13. Chills or hot flushes

Anticipatory Anxiety and Agoraphobia

Panic disorder often leads to anticipatory anxiety – anxiety over having anxiety. This can become more serious than the panic disorder itself and can lead to agoraphobia, as described by Freud. Agoraphobia differs from simple phobia in that the person is afraid they cannot escape from the situation. This can severely impact daily life, causing stress for family members as the person may be unable to be alone. It's worth noting that agoraphobia patients have a 20% suicide attempt rate, comparable to the rate in major depression.

Differential Diagnosis

It's important to differentiate panic disorder from other conditions. Panic disorder differs from GAD in its response to antidepressants and genetic studies showing no familial linkage between the two conditions. Simple Phobia and Social Phobia are usually not associated with panic attacks and are less responsive to medication. While often comorbid with major depressive disorder, panic disorder shows differences in dexamethasone suppression test results and sleep recordings.

Treatment Approaches

Pharmacological Interventions

Antidepressants

Tricyclic Antidepressants (TCAs)

TCAs, particularly imipramine, have been effective in treating panic disorder since their discovery in 1962 by Klein and Fink. TCAs have a high efficacy with 60-80% of patients showing substantial improvement, including gradual improvement in phobic avoidance. One study found that patients receiving more than 150 mg of imipramine did much better than those receiving less. Lydiard found that for desipramine, plasma levels less than 125 ng/ml were associated with better outcomes. Common side effects include weight gain, which is a common reason for discontinuation after 6 weeks of treatment. One study showed 40% of long-term patients on imipramine gained an average of 22 pounds. A key concern is that 26-70% of patients experience a return of symptoms when imipramine is discontinued.

Monoamine Oxidase Inhibitors (MAOIs)

MAOIs, such as phenelzine and tranylcypromine, have also shown efficacy in panic disorder. MAOIs may be more effective than TCAs, especially for patients with social phobia or avoidant personality features. Phenelzine has a more rapid onset of action than TCAs in blocking panic and reversing phobic avoidance. MAOIs are associated with less overstimulation than TCAs but carry a risk of hypertensive crisis if dietary restrictions are not followed. 14-100% of patients relapse when phenelzine is discontinued.

Selective Serotonin Reuptake Inhibitors (SSRIs)

SSRIs have become a first-line treatment for panic disorder due to their efficacy and more favorable side effect profile. SSRIs like fluvoxamine have shown high effectiveness in treating panic disorder. The efficacy of SSRIs supports the role of the serotonergic system in panic disorder.

Benzodiazepines

High-potency benzodiazepines, such as alprazolam and clonazepam, have demonstrated efficacy in treating panic disorder. Studies have shown alprazolam and clonazepam to be as effective as imipramine and phenelzine in treating panic disorder. Data suggest that panic disorder patients may not develop tolerance to the antipanic or antiphobic effects of high-potency benzodiazepines. For alprazolam, the usual effective dosage range is 2-6 mg per day.

Studies by Nagy et al. and Pollack et al. have shown that many patients can be maintained on benzodiazepines long-term, often with dosage reductions over time. Nagy et al. found that after 2.5 years of treatment with alprazolam and group therapy, 30% of patients were able to discontinue medication. Pollack et al. reported that among patients on clonazepam, 26% remained on the original dose, 13% were on a lower dose, and 26% required a higher dose over time [10-20].

Roy-Byrne found that after 6 weeks of treatment, a 2-week tapering period resulted in withdrawal symptoms in 57% of alprazolam patients, 40% of diazepam patients, and 0% of placebo patients. Fyer et al. reported that patients on 5-8 mg alprazolam/day for 6 months needed at least 12 weeks to taper off the drug. Tapering should occur over 4 to 24 weeks, with decreases of 0.25 to 0.5 mg/week for alprazolam or clonazepam. Sheehan found a 90% relapse rate in alprazolam patients with panic disorder after discontinuation. Ries et al. suggested that the addition of an antidepressant or carbamazepine may help with benzodiazepine tapering [8,21-23].

Psychological Interventions

Cognitive-Behavioral Therapy (CBT)

CBT has shown effectiveness in treating panic disorder, either alone or in combination with medication. Psychoeducation has been effective in understanding the nature of panic attacks and anxiety. Cognitive restructuring addresses catastrophic misinterpretations of bodily sensations. Interoceptive exposure

works with the physical sensations associated with panic along with In vivo exposures to feared situations. Furthermore, relaxation techniques and breathing retraining is also effective in the treatment for panic disorder. Studies suggest that combining CBT with medication may result in lower relapse rates compared to medication alone.

Other Psychological Approaches

Additional psychological interventions have also shown promise in treating panic disorder. These include, Systematic desensitization, Paradoxical intention techniques, which aim to help patients regain control by paradoxically encouraging them to experience panic symptoms and Family therapy to address relationship dynamics that may contribute to or maintain panic symptoms.

Combined Treatment Approaches

Evidence suggests that combining pharmacological and psychological treatments may provide the best longterm outcomes for patients with panic disorder. Pollack et al. found that patients on both benzodiazepines and antidepressants continued to improve the most on follow-up. Patients who received both behavioral therapy and medication showed longer remission periods compared to those who received either treatment alone.

Treatment Considerations

Given the often-chronic nature of panic disorder, long-term treatment strategies are often necessary. Treatment should address comorbid conditions, particularly depression. Alprazolam patients with comorbid major depression and panic disorder often continued to have depressive symptoms even with long-term treatment. Pre-existing personality traits such as perfectionism and controlling tendencies may need to be addressed in treatment. Panic disorder can be considered a "family disease," and involving family members in treatment can be beneficial. Patients should be educated that panic disorder is not a matter of "weakness" but a treatable condition with biological and psychological components.

Case Examples

UCLA Law School Graduate

A UCLA law school graduate experienced a sudden onset of panic attacks during his first year of law school. Despite maintaining excellent grades, he faced severe anticipatory anxiety that made it extremely difficult to continue his studies. He would often take up to two hours just to get from school to his therapist's office due to the overwhelming anxiety.

Long-term Agoraphobia

A 49-year-old woman had scarcely left her house in 10 years due to severe agoraphobia. She had been hospitalized and misdiagnosed as schizophrenic. After receiving the correct diagnosis of panic disorder with agoraphobia, she was treated with benzodiazepines to manage her acute anxiety symptoms. Remarkably, within two weeks of appropriate treatment, she became symptom-free.

Future Directions

Further investigation into the interaction between noradrenergic and serotonergic systems in panic disorder is important. Development of more targeted pharmacological interventions based on individual patient characteristics will be beneficial. Long-term studies on the efficacy of combined pharmacological and psychological treatments along with exploration of novel treatment approaches, including potential applications of neuroimaging findings, will help improve our understanding of this disorder and equip us with better skills to treat it.

Implementation of standardized treatment protocols that incorporate both pharmacological and psychological interventions is crucial. Development of personalized treatment plans based on individual patient factors, including comorbidities and genetic predispositions, and increased focus on long-term management strategies to prevent relapse and improve overall quality of life for patients with panic disorder will ensure consistent support for patients. [23-30].

Conclusion

Panic disorder is a complex and often chronic condition that significantly impacts the lives of those affected. This comprehensive review has highlighted the multifaceted nature of the disorder, encompassing genetic, neurobiological, and psychological factors. The interplay between noradrenergic and serotonergic systems appears to be central to the pathophysiology of panic disorder, providing targets for pharmacological interventions. Treatment approaches, including both medication (antidepressants and benzodiazepines) and cognitive-behavioral therapy, have shown efficacy in managing panic disorder. However, the high rates of relapse underscore the need for long-term management strategies and the potential benefits of combining pharmacological and psychological interventions.

The chronic nature of panic disorder, its high comorbidity with other psychiatric conditions, and its significant impact on quality of life emphasize the importance of a comprehensive, long-term approach to treatment. Future research should focus on further elucidating the neurobiological mechanisms underlying panic disorder, developing more targeted treatments, and investigating strategies to improve long-term outcomes and reduce relapse rates. Additionally, efforts to increase access to evidence-based treatments, reduce the stigma associated with panic disorder, and educate both patients and families about the nature of the disorder are crucial to improving outcomes for individuals affected by this challenging condition. By integrating our understanding of the biological, psychological, and social aspects of panic disorder, we can continue to improve our ability to effectively manage this complex and debilitating condition.

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA: American Psychiatric Publishing 2013.
2. Barlow DH. Anxiety and its disorders: The nature and treatment of anxiety and panic. Guilford Press 2002.
3. Bowlby J. Attachment and Loss: Vol. 1. Attachment. New York: Basic Books. 1969.
4. Bruce SE, Yonkers KA, Otto MW, Keller MB. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. American Journal of Psychiatry. 2005. 162: 1179-1187.

5. Fava GA, Zielezny M, Savron G, Grandi S. Long-term effects of behavioral treatment for panic disorder with agoraphobia. The Massachusetts General Hospital study. American Journal of Psychiatry. 1995. 152: 682-687.
6. Foulks EF. Arctic hysteria and "kayak angst": A review of two psycho-neurotic syndromes in the circumpolar regions. Social Science & Medicine. 1972. 6: 117-125.
7. Freud S. Inhibitions, Symptoms and Anxiety. The Standard Edition of the Complete Psychological Works of Sigmund Freud, Volume XX (1925-1926): An Autobiographical Study, Inhibitions, Symptoms and Anxiety, The Question of Lay Analysis and Other Works. 1926. 75-176.
8. Fyer AJ, Liebowitz MR, Gorman JM, Campeas R, Levin A, et al. Discontinuation of alprazolam treatment in panic patients. American Journal of Psychiatry. 1987. 144: 303-308.
9. Kagan J, Reznick JS, Snidman N. Biological bases of childhood shyness. Science. 1988. 240: 167-171.
10. Kendler KS, Prescott CA. Genes, environment, and psychopathology: Understanding the causes of psychiatric and substance use disorders. Guilford Press. 2006.
11. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry. 2005. 62: 593-602.
12. Klein DF. False suffocation alarms, spontaneous panics, and related conditions. Archives of General Psychiatry. 1993. 50: 306-317.
13. Klein DF, Fink M. Psychiatric reaction patterns to imipramine. American Journal of Psychiatry. 1962. 119: 432-438.
14. Lydiard RB, Ballenger JC, Rickels K, Schwarcz M. Comparison of desipramine and alprazolam in the treatment of panic disorder. Journal of Clinical Psychopharmacology. 1987. 7: 89-97.
15. Margraf J, Schneider S. Panic. Berlin: Springer-Verlag. 1991.
16. Moffitt TE, Caspi A, Harrington H. Generalized anxiety disorder and depression: childhood risk factors in a birth cohort followed to age 32. Psychological Medicine. 2010. 40: 1037-1050.
17. Nagy LM, Krystal JH, Woods SW, Charney DS, Heninger GR. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. Archives of General Psychiatry. 1989. 46: 993-999.
18. Noyes R, Perry PD. Comorbidity of anxiety and affective disorders: A review of shared vulnerability and nosological issues. Journal of Affective Disorders. 1998. 14: 105-115.
19. Pine DS, Klein RG. Anxiety disorders. Journal of Child Psychology and Psychiatry. 2001. 42: 641-662.
20. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolk SI, et al. Long-term outcome after acute treatment with clonazepam for panic disorder. Journal of Clinical Psychopharmacology. 1993. 13: 257-263.
21. Regier DA, Rae DS, Narrow WE, Kaelber CT, Schatzberg AF. Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. British Journal of Psychiatry. 1998. 173: 24-28.
22. Reed V, Wittchen HU. DSM-IV panic attacks and panic disorder in a community sample of adolescents and young adults: how specific are panic attacks? Journal of Psychiatric Research. 1998. 32: 335-345.
23. Ries RK, Roy-Byrne PP, Ward NG, Neppe VM, Sherman RE. Carbamazepine treatment for benzodiazepine withdrawal. Journal of Clinical Psychopharmacology. 1988. 8: 207-210.
24. Rosen R. (n.d.). Panic Disorder. [Unpublished manuscript].
25. Roy-Byrne PP, Cowley DS, Greenblatt DJ. Benzodiazepine withdrawal: overview and implications for the treatment of anxiety disorders. Journal of Clinical Psychiatry. 1990. 51: 51-57.
26. Roy-Byrne PP, Craske MG, Stein MB. Panic disorder. Lancet. 2006. 368: 1023-1032.
27. Shear MK, Gorman JM. Pharmacotherapy for panic disorder and generalized anxiety disorder. Journal of Clinical Psychiatry. 2003. 64: 24-29.
28. Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E, et al. The relative efficacy of high-dose alprazolam and imipramine in the treatment of panic disorder: a double-blind controlled study. Acta Psychiatrica Scandinavica. 1990. 82: 82-88.
29. Simon NM, Otto MW, Worthington JJ, Hofmann SG, Pollack MH. Panic disorder and social anxiety disorder: are they really co-morbid disorders? Journal of Anxiety Disorders. 2002. 16: 621-637.
30. Smoller JW, Tsuang MT. Panic and phobic anxiety: defining phenotypes for genetic studies. American Journal of Psychiatry. 1998. 155: 1152-1162.